Edwards Lifesciences Corporation (EW)
Healthcare · Medical - Devices · Data as of 2026-10-22
Bottom line
EW is trading at a premium to its history, near its historical support zone, and recent volume suggests money flowing in. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Trading at a premium (Red)
EW trades at 50× earnings, above its own 5-year average of 40× and above similar healthcare companies we track (28×, 53 peers). Investors are currently paying more per dollar of earnings than usual. Its free-cash-flow yield is about 2.9%. Its current multiple sits around the 96th percentile of its own last five years — near the top of its own range.
Price zones — Near its historical support zone (Green)
At $90.09, the stock is close to the lower end of its recent range. Over the past year EW has traded between $74.66 and $96.29; its historical support zone sits near $88.13 and resistance near $96.29. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $74.66–$96.29 · 50-day average $88.13 · 200-day average $85.21
Money flow — Money is flowing in (Green)
Recent trading in EW shows more volume on rising days than falling days, a pattern often described as accumulation. Volume on up days has been about 1.3× volume on down days over the last 30 sessions.
Dividends & company facts
EW doesn't pay a dividend, but it bought back $719 million of its shares in fiscal 2025, about 1.4% of its market value. Its share count fell 1.8% over the past year and 8.3% over five.
- Buybacks
- 1.44% (fiscal 2025)
- Shares, past year
- -1.8%
- Revenue, 12 months
- $6.5B
- Profit, 12 months
- $1.0B
- Employees
- 16,000
- CEO
- Bernard J. Zovighian
- Headquarters
- Irvine, CA
- Listed since
- 2000 · NYSE
About the company
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral…
Related stocks
一句话结论
EW 相对自身历史处于溢价水平，接近其历史支撑区，近期成交量显示资金正在流入。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 相对自身历史处于溢价水平
EW 目前的市盈率为 50×，高于其自身 5 年平均的 40×，并且高于我们追踪的同类Healthcare公司（28×，53 家）。投资者目前为每一美元盈利付出的价格高于以往。其自由现金流收益率约为 2.9%。它当前的估值倍数大约位于自身过去五年分布的第 96 百分位——接近自身区间的顶部。
价格区间 — 接近其历史支撑区
目前价格为 $90.09，接近其近期区间的下沿。过去一年 EW 的价格在 $74.66 到 $96.29 之间波动；其历史支撑区在 $88.13 附近，阻力区在 $96.29 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 资金正在流入
EW 近期上涨日的成交量高于下跌日，这种形态常被称为吸筹。过去 30 个交易日，上涨日的成交量约为下跌日的 1.3×。
股息与公司概况
EW 不派发股息，但在 2025 财年回购了 7.2亿美元 的股票，约占市值的 1.4%。其股数过去一年减少了 1.8%，五年减少了 8.3%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.